Colistin- and polymyxin-induced nephrotoxicity: Focus on literature utilizing the RIFLE classification scheme of acute kidney injury

Journal of Pharmacy Practice

Volumn 27, Issue 6, 2014, Pages 554-561

  Pike, Matthew ^a   Saltiel, Emmanuel ^b  

^a CARLE FOUNDATION HOSPITAL   (United States)

^b Pharmacy Services   (United States)

Author keywords

Colistimethate; Colistin; Nephrotoxicity; Polymyxin; RIFLE

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; COLISTIMETHATE; COLISTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMYXIN B; VANCOMYCIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ACUTE KIDNEY FAILURE; ARTICLE; BODY WEIGHT; DISEASE SEVERITY; HUMAN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEPHROTOXICITY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; RISK- NJURY FAILURE LOSS END STAGE KIDNEY DISEASE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLASSIFICATION;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; COLISTIN; HUMANS; POLYMYXIN B;

EID: 84910030886     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014546116     Document Type: Article

References (27)

1. Falagas M, Kasiakou S. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 ; 40: 1333-1341
2. Biswas S, Brunel J, Dubus J, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012 ; 10 ((8)). 917-934
3. Falagas M, Kasiakou S. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006 ; 10 ((1)). R27
4. Bellomo R, Ronco C, Kellum J, et al. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004 ; 8 ((4)). R204 - R212
5. Pogue J, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011 ; 53 ((9)). 879-884
6. DeRyke C, Crawford A, Uddin N, et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010 ; 54 ((10)). 4503-4505
7. Hartzell J, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009 ; 48 ((12)). 1724-1728
8. Kwon J, Lee J, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents. 2010 ; 35 ((5)). 473-477
9. Sorli L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013 ; 13: 380
10. Gauthier T, Wolowich W, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012 ; 56 ((5)). 2392-2396
11. Ko H, Jeon M, Choo E, et al. early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract. 2011 ; 117 ((3)). c284-8
12. Collins J, Haynes K, Gallagher J. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy. 2013 ; 33 ((8)). 812-816
13. Doshi N, Mount K, Murphy C. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy. 2011 ; 31 ((12)). 1257-1264
14. Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011 ; 1 ((1)). 14
15. Falagas M, Kasiakou S. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world.. 2006 ; 50 ((6)). 2274-2275
16. Rochester, Michigan: JHP Pharmaceuticals, LLC ; 2013:
17. Big Flats, New York: X-GEN Pharmaceuticals, Inc ; 2012:
18. Minneapolis, Minnesota: Paddock Laboratories, Inc ; 2012:
19. Lake Zurich, Illinois: Fresenius Kabi USA, LLC ; 2013:
20. Eatontown, New Jersey: Heritage Pharmaceuticals, Inc ; 2014:
21. Cortes J, Gamba G, Contreras A, et al. Amikacin nephrotoxicity in patients with chronic liver disease. Rev Invest Clin. 1990 ; 42 ((2)). 93-98
22. Oliveira J, Silva C, Barbieri C, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009 ; 53 ((7)). 2887-2891
23. Desai T, Tsang T. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med. 1988 ; 85 ((1)). 47-50
24. Lucena M, Andrade R, Cabello M, et al. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol. 1995 ; 22 ((2)). 189-196
25. Kubin C, Ellman T, Phadke V, et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012 ; 65 ((1)). 80-87
26. Akajagbor D, Wilson S, Shere-Wolfe K, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013 ; 57: 1300-1303
27. Phe K, Lee Y, McDaneld P, et al. Comparison of nephrotoxicity rates associated with colistimethate versus polymyxin B therapy: in vitro assessment and a multicenter cohort study. Antimicrob Agents Chemother. 2014 ; 58 ((5)). 2740-2746